Ariel (Ari) Kohn Email and Phone Number

Hired as Teaching Fellow for STAT 100: Introduction to Statistics and Data Science covering the end-to-end data analysis process, developing a reproducible workflow for analyzing data in R, and analyzing the ethical implications associated with data. Instructs a once-a-week section of 15 students on lecture material, grades problem sets and exams, hosts offi ce hours and reports directly to head professor, Dr. Kelly McConville.

I was the Sustainability and Strategy Fellow for a Series A venture with $50M valuation leveraging the innovation of Bitcoin to rapidly and equitably accelerate the clean energy transition. Researched and wrote company whitepaper, led beta-testing of web-platform, assembled governance structure and advisory board, compiled investor data room and pitch material, coordinated strategic corporate and NGO partnerships.

Admitted through a rigorous application process with less than 6% acceptance rate. Managed a case team of six analysts to develop recommendations using expert interviews, data analyses, quantitative models, and secondary research. Reported to C suite members of a late-stage financial technology startup, a consumer goods firm and an international financial services company with a combined market capitalization of over $7.6T.

Selected as 1 of 4 economic policy summer interns out of 400 applicants. Performed data analysis on the e ectiveness of the Inflation Reduction Act, Bipartisan Infrastructure Bill, CHIPS Act. Completed primary Reported directly to the Deputy Assistant Secretaries of macro- micro- and Energy Economic Policy. Co-authored two working papers with Senior Economist, Neal Stolleman, on industry specific market consolidation. Attended, summarized and dispersed over 15 offi ce-wide reports on hearings, think tank events and expert presentations focused on AI policy.

Close Concerns publishes Closer Look, a daily newsletter that goes out to 10,000+ healthcare leaders in the diabetes and obesity fields. I report on news, conferences, and industry dynamics related to diabetes and obesity therapies and conduct interviews with key opinion leaders, keeping researchers and members of the industry abreast of scientific breakthroughs and market dynamics.